Signal Genetics Llc (SGNL) 2.05 $SGNL
Signal Genetics FY14 results
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 9:05AM CDT
SGNL: 2.05 (-0.06)
Signal Genetics reports Q4 results
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 7:38AM CDT
SGNL: 2.05 (-0.06)
Signal Genetics Highlights Recent Achievements and Reports Full-Year 2014 Financial Results
GlobeNewswire - Mon Mar 30, 7:30AM CDT
Record Volume of MyPRS Tests Sold During the Year
SGNL: 2.05 (-0.06)
Market Maker Surveillance Report. NEON, RCON, SGNL, ORMP, FNJN, DPLO, Winning Stocks With Lowest Price Friction For Tuesday, March 24th 2015
M2 - Wed Mar 25, 3:25AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 5602 companies with "abnormal" market making, 2685 companies with positive Friction Factors and 3096 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Neonode Inc (NASDAQ:NEON), Recon Technology Ltd (NASDAQ:RCON), SIGNAL-HILL CORP (NASDAQ:SGNL), Oramed Pharmaceuticals Inc (NASDAQ:ORMP), (NASDAQ:FNJN), (NYSE
PLO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
SGNL: 2.05 (-0.06), NEON: 4.56 (-0.16), DPLO: 36.71 (+0.46), ORMP: 7.45 (+0.08), FNJN: 1.39 (-0.06), RCON: 1.90 (-0.10)
Signal Genetics Announces Exercise of Over-Allotment Option
GlobeNewswire - Mon Mar 02, 7:30AM CST
Signal Genetics, Inc. (Nasdaq:SGNL) (Signal), a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced that the underwriters of its recent public offering have exercised their option to purchase an additional 482,142 shares of its common stock at a price of $2.80 per share. The gross proceeds to Signal from the exercise of additional shares is expected to be approximately $1,350,000, before deducting underwriting discounts and commissions and other estimated offering expenses.
SGNL: 2.05 (-0.06)
Genetic Technologies Remains Among Most Difficult To Borrow Names
Interactive Brokers - at Seeking Alpha - Tue Feb 24, 12:46AM CST
Genetic Technologies Limited (NASDAQ: GENE ) continues to be one of the most sought after borrows, and while liquidity remains scarce, what little supply is available to borrow is expensive. Although the price of GENE shares has come down...
GPRO: 44.73 (-1.35), TSLA: 218.43 (-0.17), CYBR: 66.78 (+0.16), MNKD: 4.80 (-0.16), GENE: 4.70 (-0.13), BLDP: 2.18 (-0.03), WPRT: 4.46 (unch), ATOS: 1.62 (unch), SGNL: 2.05 (-0.06), RIG: 16.40 (-0.57), OPK: 14.83 (+0.17), PSTR: 4.58 (-0.05), LINE: 13.56 (-0.05), ZU: 13.59 (+0.30)
Signal Genetics finalizes equity offering
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 10:10AM CST
SGNL: 2.05 (-0.06)
Traders smitten with tiny thinly-traded biotechs
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 9:44AM CST
GENE: 4.70 (-0.13), HTBX: 6.89 (-0.71), SGNL: 2.05 (-0.06), ROSG: 3.72 (+0.06), TTPH: 40.03 (-0.67), ONCY: 0.75 (-0.05), CLRX: 0.94 (-0.01), MELA: 1.51 (+0.02), AKAO: 6.36 (-0.04), WGBS: 4.62 (+0.05), EGRX: 59.30 (-1.62)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Feb 18, 8:15AM CST
SSL: 39.58 (-0.09), AMRN: 2.33 (-0.10), GRMN: 46.19 (-0.95), FXEN: 1.36 (-0.01), NBG: 1.23 (+0.06), CVE: 19.16 (-0.11), GENE: 4.70 (-0.13), BSX: 18.34 (-0.08), ROSG: 3.72 (+0.06), ATOS: 1.62 (unch), SGNL: 2.05 (-0.06), FOSL: 83.75 (+0.43), NOR: 3.17 (-0.06), VA: 32.36 (+1.98), ANGI: 6.16 (-0.24), PBPB: 14.79 (-0.05), MDAS: 20.53 (+0.23), MSN: 1.37 (unch), CUR: 1.94 (-0.06), YNDX: 20.67 (-0.08)
Signal Genetics off on dilution from equity offering
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 12:47PM CST
SGNL: 2.05 (-0.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 11:44AM CST
CADC: 4.16 (+0.16), SCON: 1.23 (+0.03), KNDI: 12.20 (+0.04), ROIA: 3.72 (-0.27), AETI: 5.89 (+0.36), HOLI: 23.75 (-0.01), LTRX: 1.70 (-0.03), RVP: 4.30 (-0.01), EGRX: 59.30 (-1.62), VISN: 14.97 (-0.03), ROSG: 3.72 (+0.06), SGNL: 2.05 (-0.06), CLRX: 0.94 (-0.01), HLX: 16.36 (-0.32), SRPT: 13.42 (-0.24), GLF: 13.58 (-0.05), HART: 3.11 (unch), ESMC: 1.39 (+0.02), CLTX: 0.76 (+0.01), NVFY: 2.85 (+0.02)
Signal Genetics Prices $9,000,000 Public Offering
GlobeNewswire - Tue Feb 17, 11:23AM CST
Signal Genetics, Inc. (Nasdaq:SGNL) (Signal), a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced the pricing of an underwritten public offering of 3,214,285 shares of its common stock at an offering price of $2.80 per share. The gross proceeds to Signal from this offering are expected to be approximately $9,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. Signal has granted the underwriters a 45-day option to purchase up to an additional 482,142 shares of common stock to cover over-allotments, if any. The offering is expected to close on February 20, 2015, subject to customary closing conditions.
SGNL: 2.05 (-0.06)
Signal Genetics (SGNL) Stock Plunges Today After Pricing Public Offering
at The Street - Tue Feb 17, 11:16AM CST
Shares of Signal Genetics (SGNL) plummeted in early afternoon trading Tuesday after the molecular diagnostic company announced the pricing of its public offering of common stock.
SGNL: 2.05 (-0.06)
Wafergen Bio gets some Gene Tech love
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 2:47PM CST
GENE: 4.70 (-0.13), SGNL: 2.05 (-0.06), WGBS: 4.62 (+0.05)
Signal Genetics up big in early trading
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 10:42AM CST
SGNL: 2.05 (-0.06)
13 IPOs You Wish You Didn't Buy in 2014 (And Killed Your Portfolio)
at The Street - Fri Feb 06, 11:55AM CST
Here are the 13 worst performing IPO stocks in 2014.
ROKA: 3.20 (-0.10), SHAK: 68.53 (+5.80), BRDR: 6.56 (-0.28), ECR: 6.01 (-0.11), BIOC: 2.88 (-0.22), ATEN: 4.69 (-0.01), CRCM: 6.80 (-0.01), AMDA: 0.27 (-0.01), MOLG: 2.29 (-0.01), SGNL: 2.05 (-0.06), GBSN: 4.17 (-0.53), FMSA: 7.86 (-0.55), HELI: 1.11 (-0.06), REPH: 11.88 (+1.04)
Signal Genetics Receives Conditional Approval of Investigational Device Exemption for MyPRS(R)
GlobeNewswire - Mon Feb 02, 9:05AM CST
Signal Genetics, Inc. (Nasdaq:SGNL) (Signal), a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced the U.S. Federal Drug Administration (FDA) conditionally approved its proprietary prognostic genetic test, MyPRS (Myeloma Prognostic Risk Signature(R)), for use as entry criteria for an upcoming clinical trial to treat high-risk multiple myeloma (MM) patients sponsored by the University of Arkansas for Medical Sciences (UAMS).
SGNL: 2.05 (-0.06)
Signal Genetics hires Sudipto Sur as chief information officer
M2 - Wed Jan 07, 5:55AM CST
Molecular diagnostic company Signal Genetics (NasdaqCM:SGNL) disclosed on Tuesday the election of of Sudipto Sur as its chief information officer.
SGNL: 2.05 (-0.06)
Signal Genetics FY14 results
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 9:05AM CDT
SGNL: 2.05 (-0.06)
Signal Genetics reports Q4 results
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 7:38AM CDT
SGNL: 2.05 (-0.06)
Signal Genetics Highlights Recent Achievements and Reports Full-Year 2014 Financial Results
GlobeNewswire - Mon Mar 30, 7:30AM CDT
Record Volume of MyPRS Tests Sold During the Year
SGNL: 2.05 (-0.06)
Market Maker Surveillance Report. NEON, RCON, SGNL, ORMP, FNJN, DPLO, Winning Stocks With Lowest Price Friction For Tuesday, March 24th 2015
M2 - Wed Mar 25, 3:25AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 5602 companies with "abnormal" market making, 2685 companies with positive Friction Factors and 3096 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Neonode Inc (NASDAQ:NEON), Recon Technology Ltd (NASDAQ:RCON), SIGNAL-HILL CORP (NASDAQ:SGNL), Oramed Pharmaceuticals Inc (NASDAQ:ORMP), (NASDAQ:FNJN), (NYSE
PLO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . SGNL: 2.05 (-0.06), NEON: 4.56 (-0.16), DPLO: 36.71 (+0.46), ORMP: 7.45 (+0.08), FNJN: 1.39 (-0.06), RCON: 1.90 (-0.10)
Signal Genetics Announces Exercise of Over-Allotment Option
GlobeNewswire - Mon Mar 02, 7:30AM CST
Signal Genetics, Inc. (Nasdaq:SGNL) (Signal), a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced that the underwriters of its recent public offering have exercised their option to purchase an additional 482,142 shares of its common stock at a price of $2.80 per share. The gross proceeds to Signal from the exercise of additional shares is expected to be approximately $1,350,000, before deducting underwriting discounts and commissions and other estimated offering expenses.
SGNL: 2.05 (-0.06)
Genetic Technologies Remains Among Most Difficult To Borrow Names
Interactive Brokers - at Seeking Alpha - Tue Feb 24, 12:46AM CST
Genetic Technologies Limited (NASDAQ: GENE ) continues to be one of the most sought after borrows, and while liquidity remains scarce, what little supply is available to borrow is expensive. Although the price of GENE shares has come down...
GPRO: 44.73 (-1.35), TSLA: 218.43 (-0.17), CYBR: 66.78 (+0.16), MNKD: 4.80 (-0.16), GENE: 4.70 (-0.13), BLDP: 2.18 (-0.03), WPRT: 4.46 (unch), ATOS: 1.62 (unch), SGNL: 2.05 (-0.06), RIG: 16.40 (-0.57), OPK: 14.83 (+0.17), PSTR: 4.58 (-0.05), LINE: 13.56 (-0.05), ZU: 13.59 (+0.30)
Signal Genetics finalizes equity offering
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 10:10AM CST
SGNL: 2.05 (-0.06)
Traders smitten with tiny thinly-traded biotechs
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 9:44AM CST
GENE: 4.70 (-0.13), HTBX: 6.89 (-0.71), SGNL: 2.05 (-0.06), ROSG: 3.72 (+0.06), TTPH: 40.03 (-0.67), ONCY: 0.75 (-0.05), CLRX: 0.94 (-0.01), MELA: 1.51 (+0.02), AKAO: 6.36 (-0.04), WGBS: 4.62 (+0.05), EGRX: 59.30 (-1.62)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Feb 18, 8:15AM CST
SSL: 39.58 (-0.09), AMRN: 2.33 (-0.10), GRMN: 46.19 (-0.95), FXEN: 1.36 (-0.01), NBG: 1.23 (+0.06), CVE: 19.16 (-0.11), GENE: 4.70 (-0.13), BSX: 18.34 (-0.08), ROSG: 3.72 (+0.06), ATOS: 1.62 (unch), SGNL: 2.05 (-0.06), FOSL: 83.75 (+0.43), NOR: 3.17 (-0.06), VA: 32.36 (+1.98), ANGI: 6.16 (-0.24), PBPB: 14.79 (-0.05), MDAS: 20.53 (+0.23), MSN: 1.37 (unch), CUR: 1.94 (-0.06), YNDX: 20.67 (-0.08)
Signal Genetics off on dilution from equity offering
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 12:47PM CST
SGNL: 2.05 (-0.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 11:44AM CST
CADC: 4.16 (+0.16), SCON: 1.23 (+0.03), KNDI: 12.20 (+0.04), ROIA: 3.72 (-0.27), AETI: 5.89 (+0.36), HOLI: 23.75 (-0.01), LTRX: 1.70 (-0.03), RVP: 4.30 (-0.01), EGRX: 59.30 (-1.62), VISN: 14.97 (-0.03), ROSG: 3.72 (+0.06), SGNL: 2.05 (-0.06), CLRX: 0.94 (-0.01), HLX: 16.36 (-0.32), SRPT: 13.42 (-0.24), GLF: 13.58 (-0.05), HART: 3.11 (unch), ESMC: 1.39 (+0.02), CLTX: 0.76 (+0.01), NVFY: 2.85 (+0.02)
Signal Genetics Prices $9,000,000 Public Offering
GlobeNewswire - Tue Feb 17, 11:23AM CST
Signal Genetics, Inc. (Nasdaq:SGNL) (Signal), a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced the pricing of an underwritten public offering of 3,214,285 shares of its common stock at an offering price of $2.80 per share. The gross proceeds to Signal from this offering are expected to be approximately $9,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. Signal has granted the underwriters a 45-day option to purchase up to an additional 482,142 shares of common stock to cover over-allotments, if any. The offering is expected to close on February 20, 2015, subject to customary closing conditions.
SGNL: 2.05 (-0.06)
Signal Genetics (SGNL) Stock Plunges Today After Pricing Public Offering
at The Street - Tue Feb 17, 11:16AM CST
Shares of Signal Genetics (SGNL) plummeted in early afternoon trading Tuesday after the molecular diagnostic company announced the pricing of its public offering of common stock.
SGNL: 2.05 (-0.06)
Wafergen Bio gets some Gene Tech love
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 2:47PM CST
GENE: 4.70 (-0.13), SGNL: 2.05 (-0.06), WGBS: 4.62 (+0.05)
Signal Genetics up big in early trading
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 10:42AM CST
SGNL: 2.05 (-0.06)
13 IPOs You Wish You Didn't Buy in 2014 (And Killed Your Portfolio)
at The Street - Fri Feb 06, 11:55AM CST
Here are the 13 worst performing IPO stocks in 2014.
ROKA: 3.20 (-0.10), SHAK: 68.53 (+5.80), BRDR: 6.56 (-0.28), ECR: 6.01 (-0.11), BIOC: 2.88 (-0.22), ATEN: 4.69 (-0.01), CRCM: 6.80 (-0.01), AMDA: 0.27 (-0.01), MOLG: 2.29 (-0.01), SGNL: 2.05 (-0.06), GBSN: 4.17 (-0.53), FMSA: 7.86 (-0.55), HELI: 1.11 (-0.06), REPH: 11.88 (+1.04)
Signal Genetics Receives Conditional Approval of Investigational Device Exemption for MyPRS(R)
GlobeNewswire - Mon Feb 02, 9:05AM CST
Signal Genetics, Inc. (Nasdaq:SGNL) (Signal), a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced the U.S. Federal Drug Administration (FDA) conditionally approved its proprietary prognostic genetic test, MyPRS (Myeloma Prognostic Risk Signature(R)), for use as entry criteria for an upcoming clinical trial to treat high-risk multiple myeloma (MM) patients sponsored by the University of Arkansas for Medical Sciences (UAMS).
SGNL: 2.05 (-0.06)
Signal Genetics hires Sudipto Sur as chief information officer
M2 - Wed Jan 07, 5:55AM CST
Molecular diagnostic company Signal Genetics (NasdaqCM:SGNL) disclosed on Tuesday the election of of Sudipto Sur as its chief information officer.
SGNL: 2.05 (-0.06)
